Rigel Pharmaceuticals (RIGL) Operating Expenses (2010 - 2026)

Rigel Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $46.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 15.71% year-over-year to $46.9 million; the TTM figure through Mar 2026 stood at $175.2 million (up 10.08% YoY), while the FY2025 annual figure was $168.8 million, up 8.85% from the prior year.
• Operating Expenses was $46.9 million for Q1 2026 at Rigel Pharmaceuticals, up from $46.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $49.2 million in Q4 2022 to a low of $32.2 million in Q2 2023.
• Historically, Operating Expenses has averaged $40.2 million across 5 years, with a median of $40.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses sank 31.25% in 2023, then grew 26.54% in 2024.
• A 5-year view of Operating Expenses shows it stood at $49.2 million in 2022, then tumbled by 31.25% to $33.8 million in 2023, then advanced by 21.03% to $40.9 million in 2024, then gained by 13.9% to $46.6 million in 2025, then gained by 0.65% to $46.9 million in 2026.
• The last three Operating Expenses figures came in at $46.9 million (Q1 2026), $46.6 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.